ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“The addition of pembrolizumab to neoadjuvant chemotherapy in the phase III KEYNOTE-756 significantly improves the pathological complete response rate in patients with high-risk, early-stage ER+/HER2− Breast Cancer.
Read the full news on ESMO Daily Reporter.”
